Q-omics provides the consensus-scored SEPHS1P6 profile across patient tissues and cancer cell-line models. SEPHS1P6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SEPHS1P6 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SEPHS1P6 RNA expression shows 14,126 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, THCA, and GBM as cancer lineages where SEPHS1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEPHS1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEPHS1P6 survival associations across molecular data types. SEPHS1P6 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEPHS1P6 RNA expression–survival associations across cancer types. High SEPHS1P6 expression shows unfavorable associations in CESC, THCA and UVM, but favorable associations in ACC, LGG and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for SEPHS1P6 RNA expression.
This table summarizes SEPHS1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SEPHS1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEPHS1P6 shows lower tumor expression in THCA, BLCA, BRCA, LUAD, HNSC and LUSC. The THCA box plot shows higher SEPHS1P6 RNA expression in normal versus tumor tissue (log2 FC = −1.662, t-test p < 0.001).
This table shows molecular features associated with SEPHS1P6 in patient tissues and cancer cell lines. In patient samples, SEPHS1P6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
